T cell receptor-engineered T cells derived from target human leukocyte antigen-DPB1-specific T cell can be a potential tool for therapy against leukemia relapse following allogeneic hematopoietic cell transplantation.
Naoya Katsuyama(Nagoya University), Yoshiki Akatsuka(Nagoya University)
Cited by 2
Related Papers
Safety and persistence of WT1-specific T-cell receptor gene−transduced lymphocytes in patients with AML and MDS
|Blood|2017|169
Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases)
|Clinical Immunology|2004|66
Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases)
|Transplantation and Cellular Therapy|2005|1